arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

uniQure N.V.

QURE
$46.38 0.00 (0.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
44 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
32
Health
Poor
Bearish
auto_awesome

Analytical Summary

uniQure N.V. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.9B
Dividend Yield
Revenue Growth 127.3%
Op. Margin None
ROIC -23.2%
FCF / Share $-0.61
Trailing P/E
Price / Book 19.6x
FCF Yield
Debt / Equity 0.33
info Valuation on last close. End-of-day price, Aug 7, 2026.

44-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$3.56M
↑ +127.3%
Net Income Profit after all expenses
$-53.53M
↓ -22.7%
Operating Margin Operating profit as % of sales
-395.6%
↓ -561.0%
FCF / Share Free cash flow per share
$-0.61
↑ +26.5%
Long-Term Debt Long-term obligations
$49.94M
↓ -30.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
9
Financial Health
46
Cash Quality
60

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 13 years · 44 quarters